Humanized Mouse Models for Immuno-Oncology Research

Humanized Mouse Models for Immuno-Oncology Research represent one of the most translationally relevant immuno-oncology tools 

Home » Oncology CRO Services » Humanized Mouse Models for Immuno-Oncology Research

Humanized mouse models for immuno-oncology research are immunodeficient mice, with reconstituted human immune system (e.g., via PBMCs or CD34+ hematopoietic stem cells) co-engrafted with human tumors using either human cell lines or patient-derived tumor samples. Alternatively, transgenic knock-in humanized mouse models carrying human genes (such as human PD-1) are also available. This approach allows you to test your novel therapies with distinct patient tumor tissues and the human immune system of your choosing as the most accurate and specific representation of the patient tumor and immune system.  

Using patient-derived xenografts or cell line-derived xenografts, human tumor cells or tissues are implanted in mice that feature an intact humanized immune system, representing a powerful tool for immuno-oncology research. Compared to other models where immunodeficient mice are used, humanized mice represent more advanced models, with InnoSer’s expert recommendation to be used in the advanced stages of your preclinical research.

Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.  

Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions in the most cost-effective way. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio. 

Services with humanized mouse models for immuno-oncology research that InnoSer offers:  

  • Implantation of human tumors established from human cancer cell lines (cell line-derived xenograft mouse model) into humanized mice. 
  • Implantation of patient-derived tumors (patient-derived xenografts) into humanized mice. 
  • Complementary PK/PD services. 

Find the right model for you.

Compare our model capabilities and discover which of our oncology platforms suits your research needs

oncology leaflet download

Key readouts in Humanized Mouse Models for Immuno-Oncology Research  

Test the efficacy of your treatments with the following readouts: 

  • Myeloid cell lineage boosting via cytokines (IL-4, IL-3, GM-CSF etc.,)  
  • Response to treatment (tumor growth kinetics, body weight, clinical signs, survival analyses) 
  • Biomarker histopathology 
  • Immune cell and cytokine profiling 

Related model options

Oncology Platform Overview

Highly relevant oncology CRO services to facilitate preclinical drug development.

Cell line-derived Xenograft (CDX) Mouse Models

CDX models represent one of the first steps to evaluate the efficacy using in vivo models of human cancer.

Patient-derived Xenograft (PDX) Mouse Models

Recapitulate the tumor and patient heterogeneity using patient-derived xenograft (PDX) mouse models.

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.


Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

Need more information?

If you have any questions about how we can help accelerate your research,

then let us know